Syndax Pharmaceuticals (SNDX) Competitors $15.40 +0.09 (+0.56%) As of 12:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SNDX vs. MTSR, PCVX, KRYS, PTCT, ARWR, ACLX, AKRO, CRNX, PTGX, and KYMRShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Metsera (MTSR), Vaxcyte (PCVX), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR), Arcellx (ACLX), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Protagonist Therapeutics (PTGX), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Its Competitors Metsera Vaxcyte Krystal Biotech PTC Therapeutics Arrowhead Pharmaceuticals Arcellx Akero Therapeutics Crinetics Pharmaceuticals Protagonist Therapeutics Kymera Therapeutics Metsera (NASDAQ:MTSR) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations. Is MTSR or SNDX more profitable? Metsera has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -428.48%. Metsera's return on equity of 0.00% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MetseraN/A N/A N/A Syndax Pharmaceuticals -428.48%-130.47%-56.12% Do analysts prefer MTSR or SNDX? Metsera currently has a consensus price target of $55.75, suggesting a potential upside of 5.65%. Syndax Pharmaceuticals has a consensus price target of $39.22, suggesting a potential upside of 154.77%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Metsera.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metsera 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.38Syndax Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Which has preferable earnings and valuation, MTSR or SNDX? Metsera has higher earnings, but lower revenue than Syndax Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMetseraN/AN/A-$209.13MN/AN/ASyndax Pharmaceuticals$23.68M56.00-$318.76M-$3.89-3.96 Does the media refer more to MTSR or SNDX? In the previous week, Metsera and Metsera both had 4 articles in the media. Metsera's average media sentiment score of 0.85 beat Syndax Pharmaceuticals' score of 0.62 indicating that Metsera is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metsera 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMetsera and Syndax Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks. Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.33B$3.40B$6.05B$10.50BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-3.9622.8585.1627.28Price / Sales56.00269.65518.10200.08Price / CashN/A46.9537.5761.53Price / Book4.5510.5412.406.82Net Income-$318.76M-$52.58M$3.32B$276.69M7 Day Performance-6.70%0.57%0.52%0.18%1 Month Performance-2.81%15.45%10.05%8.18%1 Year Performance-22.05%17.98%75.51%34.82% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals3.6278 of 5 stars$15.40+0.6%$39.22+154.8%-22.8%$1.33B$23.68M-3.96110MTSRMetseraN/A$52.46-0.7%$55.75+6.3%N/A$5.51BN/A0.0081PCVXVaxcyte2.1197 of 5 stars$42.29+3.8%$106.25+151.3%-62.1%$5.49BN/A-10.29160Analyst ForecastKRYSKrystal Biotech4.4507 of 5 stars$186.96-0.1%$209.00+11.8%+4.7%$5.42B$290.52M38.03210Analyst RevisionPTCTPTC Therapeutics3.4135 of 5 stars$65.19+1.1%$69.00+5.8%+68.9%$5.18B$806.78M9.351,410Analyst RevisionARWRArrowhead Pharmaceuticals3.992 of 5 stars$36.53-1.1%$43.14+18.1%+85.7%$5.04B$572.98M-28.50400ACLXArcellx2.1765 of 5 stars$87.53-0.9%$112.69+28.7%+0.6%$4.85B$56.98M-25.5780Analyst RevisionAKROAkero Therapeutics3.6797 of 5 stars$54.21+16.6%$78.43+44.7%+79.3%$4.34BN/A-27.1130Insider TradeHigh Trading VolumeCRNXCrinetics Pharmaceuticals3.7538 of 5 stars$45.60+2.6%$74.45+63.3%-17.0%$4.29B$1.04M-11.09210PTGXProtagonist Therapeutics1.6843 of 5 stars$67.06+2.7%$68.83+2.6%+66.0%$4.18B$434.43M96.01120Analyst ForecastInsider TradeGap DownKYMRKymera Therapeutics1.472 of 5 stars$57.06+1.4%$61.26+7.4%+26.5%$4.08B$47.07M-16.44170Insider Trade Related Companies and Tools Related Companies MTSR Alternatives PCVX Alternatives KRYS Alternatives PTCT Alternatives ARWR Alternatives ACLX Alternatives AKRO Alternatives CRNX Alternatives PTGX Alternatives KYMR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNDX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
